Ignitis Group honored twice at IR Impact Awards Europe 2025

Darius Maikštėnas CEO
Darius Maikštėnas CEO
0Comments

Ignitis Group has been recognized for its investor relations practices, receiving accolades at the IR Impact Awards Europe 2025. The company was shortlisted in four categories: Best ESG reporting (mid-cap), Best innovation in shareholder communications, Best IR website (small to mid-cap), and Best retail IR strategy.

At the awards ceremony on June 26 in London, often referred to as ‘the Oscars’ for publicly listed companies, Ignitis Group joined other notable firms like Iberdrola, EDP, and RWE.

The nominations highlight Ignitis Group’s recent initiatives. In 2024, their Sustainability Statement aligned with the Corporate Sustainability Reporting Directive (CSRD) for the first time. The company also hosted a large-scale Investor Day for retail investors in Lithuania and launched an investor newsletter. Their website was redesigned to enhance digital communication standards.

Ainė Riffel-Grinkevičienė, Chief of Staff to CFO and Head of Investor Relations at Ignitis Group stated: “Being the recognised for the second time in investor relations across four categories among European companies is an outstanding achievement for which we are truly grateful. This recognition affirms our commitment to building transparent and strong relationships with both institutional and retail investors, whose engagement continues to grow. We remain dedicated to applying the best practices in investor relations and leading the way with impactful initiatives.”

The IR Impact Awards acknowledge excellence in investor relations throughout Europe. Nominees are chosen by industry experts based on thorough research and stakeholder feedback.

Two years prior, Ignitis Group was nominated for the Best ESG reporting (mid-cap) award, reinforcing its commitment to sustainability and transparent communication.

Further details about the awards can be found at IR Impact Awards Europe 2025.



Related

Paul Hudson Chief Executive Officer Sanofi SA

Acoziborole receives key EU panel backing as single-dose treatment for sleeping sickness

Acoziborole Winthrop, a new oral treatment for sleeping sickness developed by the Drugs for Neglected Diseases initiative (DNDi) and Sanofi, has received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for…

Martin Lundstedt President and CEO at Volvo Group North America LLC Volvo Group North America LLC

Volvo announces updated share and vote count after series conversion

The number of votes in AB Volvo has changed following the conversion of 2,000,619 Series A shares into an equal number of Series B shares.

Paul Hudson Chief Executive Officer Sanofi SA

Sanofi and Regeneron’s Dupixent recommended for EU approval in young children with chronic urticaria

Sanofi and Regeneron have announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of Dupixent (dupilumab) for children aged two to 11 years with…

Trending

The Weekly Newsletter

Sign-up for the Weekly Newsletter from EU Business Daily.